Paul Song

Company: Genequantum Healthcare

Job title: Chief Scientific Officer

Seminars:

Next-Generation Bispecific and DLL3-Targeting ADCs for Lung Cancer: Preclinical Advances 4:00 pm

High-throughput ADC discovery at GQ enables rapid development of high quality next-gen ADCs Demonstration of strong preclinical efficacy in NSCLC and SCLC PDX models Larger therapeutic window based on stable linker, optimized DAR and antibody affinityRead more

day: Scientific Program Day Two PM

12:00pm Panel Discussion: Overcoming Challenges in Developing Dual-Payload ADCs for Enhanced Therapeutic Efficacy 12:00 pm

Exploring the potential advantages of dual-payload ADCs over conventional single-payload ADCs, particularly in overcoming secondary drug resistance Discussing strategies for selecting and optimizing payloads to achieve a balanced therapeutic profile, considering different mechanisms of action and toxicity profiles Highlighting preclinical data requirements to validate dual-payload ADCs, emphasizing the need for compelling evidence to support their…Read more

day: Day Two Preclinical & Clinical Development Track